Since the start of September, the luster has disappeared from Exact Sciences' stock. This pullback provides an opportunity to own a company that is growing on multiple levels.
News & Analysis: Exact Sciences
Exact Sciences and GW Pharmaceuticals received regulatory approvals that will allow the companies to expand sales of successful products.
It was a great month to be a genetic testing company.
EXAS earnings call for the period ending June 30, 2019.
At first glance, an acquisition announcement looked like the wrong deal.
Shares are heading in opposite directions after the two cancer diagnostic companies surprised Wall Street by revealing plans to merge. Here's what investors need to know.
The biotech's recent momentum is showing no signs of cooling off, despite its jaw-dropping valuation.
Easier ways to look for solid tumors are closer than you think.
These look like great picks to buy in May before you go away.
A new study is planned that could someday reshape colon cancer screenings.